Proactiveinvestors Australia

pSivida Corporation www.psivida.com

pSivida Corporation (ASX: PVA) develops tiny, sustained release drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. pSivida is currently focused on the treatment of chronic diseases of the back of the eye utilising its core technology systems, Durasert™ and BioSilicon™.

Tweet

 

Email

Email to a friend:

To:

Separate multiple addresses with commas.

From Email address:

Name: Please send me a copy Message:

Verification code

Enter the code from aboveRequired

Send

pSivida Corporation enters second partnership to assess drug delivery technology for eye diseases

pSivida Corporation (ASX: PVA, NASDAQ: PSDV) will evaluate the use of its Durasert™ drug delivery technology in ophthalmology in partnership with U.S.-based ocular drug development company Neuron Systems.

The two companies entered an agreement to assess the use of pSivida’s technology as a delivery system for the treatment of dry age related macular degeneration (Dry AMD), a serious retinal disease that afflicts millions of patients worldwide and can lead to blindness.

There is currently no treatment on the market for Dry AMD, which affects more people than Wet AMD, a condition that affects less than 20% of the population with AMD and is well treated with products such as Genentech’s billion dollar Lucentis and Regeneron’s Eylea.

This is the second technology evaluation agreement pSivida has signed for its bioerodible Durasert technology since the company regained the rights to its intellectual property from Pfizer last year.

In November the company signed a funded technology evaluation agreement with a leading global pharmaceutical company.

Durasert™ is a fully bioerodible implantable delivery device system that is small enough to fit inside the barrel of a 25 gauge needle.

pSivida is using the technology to develop a long term sustained release implant of latanoprost, the most commonly prescribed agent for ocular hypertension and glaucoma.

Sign up to Proactive Investors

Comments from Proactive Investors readers

• Fill in your details below:

Verification Code

Reload image